This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Discover Pfizer's innovative patent for multi-drugAntibodyDrug Conjugates and Linking Assembly Units, enabling precise and effective drugdelivery. Explore the cutting-edge technology behind site-specific construction and versatile drug linking options.
Memo Therapeutics AG will receive CHF 10.5m (US $11.4m) from the Swiss government to clinically develop a SARS-CoV-2 antibody against COVID-19, allowing it to start Phase 1 studies in Q1, 2022.
Genentech’s ocular implant drugdelivery system for treatment of macular degeneration has received approval from the US Food and Drug Administration (FDA). Susvimo delivers ranibizumab via a port delivery system into a surgically placed implant in the eye, allowing for continuous delivery of the drug.
Given the robust pipeline of biologics, which include monoclonal antibodies, vaccines and other protein-based therapeutic products, subcutaneous medications are being investigated for various clinical candidates across different phases of development. You can also download the SAMPLE REPORT on subcutaneous medications by Roots Analysis.
Furthermore, a wide variety of drugs and macromolecules, including DNA , proteins, and imaging agents, can be encapsulated in liposomal vesicles due to their unique ability to entrap both lipophilic and hydrophilic substances. The various therapeutic applications of liposomes in drugdelivery have been highlighted in the figure.
This year, Matt Cooper, PhD , our Executive Director, Therapeutic Strategy Lead, Oncology, attended and found the presentations around antibody-drug conjugates (ADCs) and tumor-infiltrating lymphocytes (TILs) to be of great interest to the future of oncology therapeutics.
The US Food and Drug Administration (FDA) has approved Galderma’s monoclonal antibody Nemluvio (nemolizumab) for the treatment of adult patients with the chronic skin condition prurigo nodularis. Monoclonal antibody therapy has been found to have fewer side effects when compared to immunosuppressant drugs.
In addition, NLCs offer benefits such as high drug loading capacity, improved drug retention and avoidance of drug expulsion. Advantages of Lipid Nanoparticle LNPs are gaining significant attention of formulation scientists in drugdelivery due to the various advantages offered by them.
seroresponse rate indicating the proportion of participants achieving antibody levels above a predefined protective threshold sustained one year after vaccination. One year post-vaccination, antibody levels remained strong, with geometric mean titers well above the required protective threshold. The findings reveal a remarkable 98.3%
Texas-based Abexxa has been on the Boehringer’s radar since it was set up, as it provided seed funding for the preclinical-stage company in 2016, buying into its approach of developing antibodies against targets inside cancer cells, rather than on the cell membrane. Last December, Boehringer paid €1.8
However, several drugdelivery devices that enable patients to self-administer their respective medications are now available. Subcutaneous drugdelivery systems – the helping hand for patients. The emergence of safer and patient-friendly devices is acting as a strong enabler for subcutaneous delivery of therapeutics.
Nucala, a monoclonal antibody indicated for patients with chronic rhinosinusitis with nasal polyps, has been approved by the Food and Drug Administration.
The 3 rd Annual Blood-Brain Barrier Summit is dedicated to helping drug developers enhance drugdelivery across the Blood-Brain Barrier (BBB) to enable effective treatments for neurodegenerative diseases. New for this year we also explore the mechanisms of SARS-CoV-2 brain entry. DOWNLOAD THE PROGRAM HERE.
Sarclisa is a CD38-directed antibody that is currently approved as an intravenous therapy for relapsed multiple myeloma in combination with either Bristol-Myers Squibb’s Pomalyst (pomalidomide) plus dexamethasone or Amgen’s Kyprolis (carfilzomib) plus dexamethasone. .
HitGen & UPPTHERA Collaborate for DrugDelivery Research. HitGen has entered into a collaboration for drug discovery research with UPPTHERA to identify small molecule Hits against previous known-to-be undruggable targets and novel E3 ligase.
One of the biggest challenges with developing therapies to treat CNS disorders is the delivery of systemically administered investigational products (IPs) to the brain, which is limited by the blood-brain barrier. Some methods of direct CNS administration include intrathecal, intraparenchymal and intracerebroventricular (ICV) delivery.
To achieve this, the agenda will allow delegates to: Explore the translation of BBB-penetrating antibodies to non-human primates , and new possibilities for in vivo brain imaging of antibody neuropharamacokinetics. 3-day Conference | June 28-30, 2021.
Vaxart said in November it had completed enrolment in a phase 1 trial of its oral COVID-19 vaccine VXA-CoV2-1, having reported viral load reduction and antibody responses in a COVID-19 hamster challenge model. ImmunityBio’s vaccine design drives both antibody and T-cells to the spike (S) protein and nucleocapsid (N) protein.
The team also learned about the FDA approval of Genentech’s new ocular implant drugdelivery system, called Susvimo, for the treatment of neovascular, or wet, age-related macular degeneration (nAMD). Genentech’s New Ocular Implant DrugDelivery System for Macular Degeneration Could Be a Game Changer.
In order to promote the use of exosomes in various therapeutic applications including targeted drugdelivery vehicles, engineered exosomes and many more, there are a number of companies that offer services related to the isolation, purification, characterization or quantification of exosomes. Our Social Media Platform. Web: [link].
GlaxoSmithKline (GSK) has reported encouraging data for its COVID-19 antibody sotrovimab, and an alliance with Halozyme to develop a new generation of long-acting HIV drugs, as it prepares to give a much-anticipated update to shareholders tomorrow. So far, all the other antibodies are also delivered by intravenous infusion.
The results were disappointing, with only a minority of patients getting the intranasal regimen showing signs of SARS-CoV-2 antigen-specific antibody responses in the mucosa, which according to the researchers “rarely” exceeded the levels one would see after a COVID-19 infection.
Ocrevus Zunovo uses Halozyme Therapeutics’ Enhanze drugdelivery technology , which enhances absorption by temporarily increasing the permeability of the subcutaneous tissue. The enzyme rHuPH20 enables rapid dispersion of the drug into the bloodstream. The global multiple sclerosis (MS) drug market expects growth from $21.16
AdCOVID was able to stimulate antibodies that bound the SARS-CoV-2 spike protein and were able to neutralise the virus, but not in sufficient quantities and in too few patients.
Studies Show Cyto-111 Enables Delivery of Antibodies to Previously Inaccessible Intraneuronal Targets without the need for a Viral Vector or Transfection.
The complete text of the article titled, “Neuronal Delivery of Antibodies has Therapeutic Effects in Animal Models of Botulism,” can be found h e re.
Thrombocytopenia pipeline possesses potential drugs in mid-stage developments to be approved shortly. Efgartigimod (ARGX-113) is an investigational therapy for IgG-mediated autoimmune diseases, designed to leverage the natural interaction between IgG antibodies and the recycling receptor FcRn.
With the aim of achieving a higher quality of life for those with unfavourable prognoses, this project, funded by Innovate UK, the UK’s innovation agency, brings together partners with a wealth of experience and specialist know-how in the areas of nanoparticle development, drugdelivery and bioimaging.
Roche has secured EU approval for Phesgo, a fixed-dose combination of its breast cancer drugs Herceptin and Perjeta that is easier and cheaper to administer to patients – and also provides a defence against biosimilar competition. The post Roche claims EU okay for Herceptin/Perjeta combination Phesgo appeared first on.
In the last decade alone, the annual number of approvals of biopharmaceuticals (including monoclonal antibodies, recombinant proteins, vaccines and gene therapies), by the US FDA, have steadily risen. Over the years, the rising popularity of biologics has led to a paradigm shift in the healthcare industry. Our Social Media Platform.
As projected by Roots Analysis, antibodies will have the highest share in this market. Further, majority of capacity is available with service providers headquartered in Asia-Pacific. This trend is likely to continue in the future.
Conjugation is the process of formation of a single, stable hybrid, wherein one of the entities is a molecule, such as protein, antibody, peptide and small molecule. Bioconjugation is a subset of conjugation where one of the entity is a biomolecule, such as protein or an antibody.
In the dynamic landscape of the healthcare sector, the evolution of drugdelivery systems plays a significant role in transforming the management of chronic diseases. These devices reduce injection anxiety, and are useful for patients who prefer a hands-free drugdelivery experience.
It has become the de facto standard equipment for high titer transient protein expression platforms used by many leading Chinese antibodydrug pharmaceutical companies and IVD (In Vitro Diagnostics) companies since its launch in Oct.
Over the last two decades the pharmaceutical industry has observed a paradigm shift from conventional drugdelivery strategies to more enhanced, potent, and targeted therapeutics. This led the researchers to find alternative pathways and drugdelivery strategies to enhance the potent delivery of the drug to the site of action.
For the Sarclisa ® subcutaneous formulation delivery, Sanofi has partnered with drugdelivery technology innovator company Enable Injections , Inc. to advance the development of a subcutaneous delivery for Sarclisa ® with the goal of offering a unique patient-centric treatment experience. John Reed , MD , Ph.
Therapies such as dexamethasone drugdelivery system and vascular endothelial growth factor inhibitors have already pierced deeper into the market. Brolucizumab is a humanized single-chain antibody fragment (scFv).
Advances in DrugDelivery (Session #ADT08), with a discussion on the advances and innovations fueling the development of the next generation of antibodydrug conjugates. The introduction of AZD8853, a novel antibody targeting GDF15 for tumours refractory to immunotherapy treatment.
” Mr. Bliss joins TLC following interim roles in cellular therapy, drugdelivery and combination therapy where he led efforts to confirm research outcomes and partner the various technologies. Earlier in his career, he ran business-development functions at Amgen and Baxter.
Roots Analysis – Leaders in Pharmaceutical & Biotechnology Market Research You may also be interested in the following titles: Continuous Manufacturing (Small Molecules and Biologics) Market Subcutaneous Biologics, Technologies and DrugDelivery Systems Market Antibody Discovery Services and Platforms Market Our Social Media Platform Web: (..)
Oxsonics Therapeutics, which offers an ultrasound-based drugdelivery platform, appointed Jérôme Marzinski, a board member at Cimon Medical and former CEO of ophthalmic diagnostic company Visiometrics into its top job. More CEO shakeups. Bungay formerly served as CEO of Chroma Therapeutics and COO of Mereo Biopharma.
However, the Crohn’s disease market space experienced strides of research and developments imbibed with continuous innovation in terms of drugdelivery platforms, MoAs, and RoAs with an end goal to minimize the numbers of patients experiencing no-response from the treatment.
Key Growth Drivers Autoinjectors Market Ease of Use: The benefits of using autoinjectors over conventional methods of parenteral drugdelivery are widely recognized by healthcare industry professionals as well as end-users.
This can be attributed to the fact that liposomes can actively target tumor tissues when used in combination with antibodies. Majority of the articles (51%) are focused on evaluating liposomes for use in cancer therapy. These platforms have created an opportunity for the product developers to share their innovative ideas in this domain.
Darzalex Faspro is the only CD38-directed antibody that has been approved for subcutaneous injection for multiple myeloma, and now AL amyloidosis. It is co-formulated with recombinant hyaluronidase PH20 (rHuPH20), Halozyme’s ENHANZE drugdelivery technology.
We organize all of the trending information in your field so you don't have to. Join 21,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content